Khoo Shih has over 20 years of experience investing in private and public life sciences and healthcare companies globally. At Temasek, she was Managing Director, Life Sciences Investments and successfully grew the life sciences portfolio and led biopharma and early-stage innovation investments and strategies. She was instrumental in conceiving and founding ClavystBio at Temasek.
Before joining Temasek, Khoo Shih was with UOB Venture Management, where she was responsible for investing in life sciences venture and growth companies in China and the US. Her business career began in the Biomedical Sciences cluster at the Singapore Economic Development Board, as part of the team that spearheaded the growth of the biomedical industry in Singapore.
Khoo Shih holds a PhD in Genetics and Development from the University of Texas Southwestern Medical Center and a BSc in Microbiology from the National University of Singapore. She currently serves on the Board of Directors of Bisirna, Cirrus Therapeutics, Nuevocor, and Paratus Sciences, and the Supervisory Board of Leyden Labs.
